Cat. No.: HY-N0162

Luteolin

(Synonyms: Luteoline; Luteolol; Digitoflavone)

90 Cited Publications

Customer Review

Based on 90 publication(s) in Google Scholar

Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells.

For research use only. We do not sell to patients.

Purity: 99.51%
CAS No.: 491-70-3
Formula: C₁₅H₁₀O₆
Molecular Weight:286.24

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Luteolin Chemical Structure

CAS No.: 491-70-3

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (90)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	12.9 mg/mL Compound: 17	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 15568778]
A549	IC₅₀	10.23 μg/mL Compound: Luteolin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21106454]
B16-4A5	IC₅₀	>100 μM Compound: 15	Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay	[PMID: 20189399]
B16-4A5	IC₅₀	14 μM Compound: 15	Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs	[PMID: 20189399]
B16-4A5	IC₅₀	14 μM Compound: 2	Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis	[PMID: 25987378]
BXPC-3	GI₅₀	>10 μg/mL Compound: 4	Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay	[PMID: 12608861]
C8166	CC₅₀	17.9 μg/mL Compound: 3	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	2.48 μg/mL Compound: 3	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
Ca9-22	IC₅₀	8.55 μg/mL Compound: Luteolin	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 21106454]
CCRF-CEM	IC₅₀	>10 μg/mL Compound: 9	Cytotoxicity against human CEM cells after 3 days by MTT assay Cytotoxicity against human CEM cells after 3 days by MTT assay	[PMID: 11421746]
CHO	EC₅₀	1.45 μM Compound: 8	Agonist activity at rat DAT expressed in CHO cells Agonist activity at rat DAT expressed in CHO cells	[PMID: 20971650]
DU-145	GI₅₀	4.4 μg/mL Compound: 4	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 12608861]
Erythrocyte	EC₅₀	122 μg/mL Compound: Luteolin	Antioxidant activity in erythrocytes assessed as inhibition of hemolysis Antioxidant activity in erythrocytes assessed as inhibition of hemolysis	[PMID: 22677320]
Erythrocyte	EC₅₀	107.28 μg/mL Compound: Luteolin	Hemolysis of human erythrocytes after 30 mins by spectrophotometry Hemolysis of human erythrocytes after 30 mins by spectrophotometry	[PMID: 23811092]
H9	EC₅₀	10 μM Compound: 3	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	16 μM Compound: 3	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9c2	EC₅₀	5.53 μM Compound: 16	Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20932762]
HCT-116	EC₅₀	26.7 μM Compound: Luteolin	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26529431]
HEK293	IC₅₀	0.85 μM Compound: 7e	Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay	[PMID: 20731357]
HEK293	EC₅₀	2.3 μM Compound: 16	Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay	[PMID: 24955889]
HEK293	IC₅₀	>10 μM Compound: 25	Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay	[PMID: 30943030]
HeLa	IC₅₀	16.254 μM Compound: Luteolin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 31784199]
Hep 3B2	IC₅₀	8.03 μg/mL Compound: Luteolin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21106454]
HepG2	IC₅₀	7.36 μg/mL Compound: Luteolin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21106454]
HepG2	IC₅₀	71.2 μM Compound: 31	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21726077]
HepG2	IC₅₀	80.8 μM Compound: 8	Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24974349]
HepG2	IC₅₀	34.7 μM Compound: Luteolin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26896708]
HepG2	IC₅₀	47.3 μM Compound: 16	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
HL-60	IC₅₀	12.1 μg/mL Compound: 12	Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release	[PMID: 10650074]
HL-60	IC₅₀	>10 μg/mL Compound: 9	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 11421746]
HL-60	IC₅₀	>100 μM Compound: Luteolin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27353532]
HT-29	EC₅₀	7.24 μM Compound: Luteolin	Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay	[PMID: 24900447]
HT-29	IC₅₀	18.6 μM Compound: Luteolin	Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins	[PMID: 24900447]
HT-29	IC₅₀	45 μM Compound: 40	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 31324564]
Huh-7	CC₅₀	>50 μM Compound: 22	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	4.7 μM Compound: 22	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Huh-7	EC₅₀	6.6 μM Compound: 22	Antiviral activity against HCV genotype 2a J399LM in Human Huh7.5.1 replicon cells assessed as suppression of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV genotype 2a J399LM in Human Huh7.5.1 replicon cells assessed as suppression of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 22445328]
Jurkat	IC₅₀	1.3 μM Compound: Luteolin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	1.5 μM Compound: Luteolin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
K562	IC₅₀	14.65 μM Compound: 2, luteolin	Growth inhibition of K562 cells by XTT assay after 5 days Growth inhibition of K562 cells by XTT assay after 5 days	[PMID: 17411092]
KB	IC₅₀	45.3 μM Compound: 16	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
KM-20L2	GI₅₀	>10 μg/mL Compound: 4	Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay	[PMID: 12608861]
L02	IC₅₀	>100 μM Compound: Luteolin	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 26896708]
L6	IC₅₀	21.4 μg/mL Compound: 21	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method	10.1039/C5MD00481K
L6	IC₅₀	9.4 μg/mL Compound: 21	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis	10.1039/C5MD00481K
L929	EC₅₀	>250 μM Compound: luteolin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	[PMID: 9287415]
L929	EC₅₀	>250 μM Compound: luteolin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	[PMID: 9287415]
LNCaP	IC₅₀	5 μM Compound: 2	Downregulation of prostate specific antigen secretion in human LNCAP cells Downregulation of prostate specific antigen secretion in human LNCAP cells	[PMID: 25019478]
Lu1	IC₅₀	40.8 μM Compound: 16	Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	GI₅₀	9.4 μg/mL Compound: 4	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 12608861]
MCF7	IC₅₀	14.3 mg/mL Compound: 17	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 15568778]
MCF7	IC₅₀	9.5 μg/mL Compound: Luteolin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21106454]
MCF7	IC₅₀	44.4 μM Compound: 16	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	IC₅₀	5 μM Compound: Luteolin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MDA-MB-231	IC₅₀	9.65 μg/mL Compound: Luteolin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 21106454]
MDA-MB-231	IC₅₀	7.29 μM Compound: Luteolin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34971873]
MDCK	CC₅₀	12.44 μM Compound: 2	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 18640042]
MDCK	CC₅₀	164.9 μM Compound: 2	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 19729316]
MDCK	EC₅₀	103.1 μM Compound: 2	Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	EC₅₀	84 μM Compound: 2	Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MOLM-13	IC₅₀	4.5 μM Compound: 25	Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026809]
Monocyte	IC₅₀	1.5 μM Compound: luteolin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Monocyte	IC₅₀	1.5 x 10^-6 M Compound: luteolin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
MV4-11	GI₅₀	1.76 μM Compound: 3	Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
MV4-11	IC₅₀	3.1 μM Compound: 25	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026809]
NCI-H460	GI₅₀	3.8 μg/mL Compound: 4	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 12608861]
NCI-H460	IC₅₀	8.9 μM Compound: 11	Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C	[PMID: 21275386]
Neutrophil	IC₅₀	0.9 μM Compound: 4e	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	4 μM Compound: 4e	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	9.3 μM Compound: 4e	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	9.5 μM Compound: 4e	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	1.7 μM Compound: 6	Inhibition of PMA-induced oxidative burst in human neutrophils by amplex red assay Inhibition of PMA-induced oxidative burst in human neutrophils by amplex red assay	[PMID: 25151578]
Neutrophil	IC₅₀	2.2 μM Compound: 6	Inhibition of PMA-induced oxidative burst in human neutrophils by APF assay Inhibition of PMA-induced oxidative burst in human neutrophils by APF assay	[PMID: 25151578]
Neutrophil	IC₅₀	5.2 μM Compound: 6	Inhibition of PMA-induced oxidative burst in human neutrophils by chemiluminescence assay Inhibition of PMA-induced oxidative burst in human neutrophils by chemiluminescence assay	[PMID: 25151578]
P388	GI₅₀	>10 μg/mL Compound: 4	Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay	[PMID: 12608861]
Peritoneal macrophage	IC₅₀	20 μM Compound: kp17	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
Peritoneal macrophage	IC₅₀	77.7 μM Compound: luteolin	Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay	[PMID: 22989363]
Platelet	IC₅₀	>50 μg/mL Compound: Luteolin	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	2.56 μg/mL Compound: Luteolin	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	43.5 μM Compound: 6	Inhibition of arachidonic acid-induced platelet aggregation in rabbit plasma preincubated 3 mins before addition of thrombin by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit plasma preincubated 3 mins before addition of thrombin by turbidimetric method	[PMID: 9287421]
RAW264.7	IC₅₀	7.39 μM Compound: 16	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite formation Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite formation	[PMID: 18348534]
RAW264.7	IC₅₀	7.5 μM Compound: 6	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method	[PMID: 19778086]
RAW264.7	IC₅₀	10.4 μM Compound: Luteolin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent	[PMID: 20363145]
RAW264.7	IC₅₀	43.2 μM Compound: luteolin	Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay	[PMID: 22989363]
RAW264.7	IC₅₀	0.21 μM Compound: 8	Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method	[PMID: 25176187]
RAW264.7	IC₅₀	7.2 μM Compound: 12	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by Griess reaction based method Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by Griess reaction based method	[PMID: 25637363]
RAW264.7	IC₅₀	18.95 μM Compound: Luteolin	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 28408221]
RAW264.7	IC₅₀	2.87 μM Compound: Luteolin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	5.06 μM Compound: Luteolin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	5.6 μM Compound: Luteolin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 28960981]
RAW264.7	IC₅₀	>50 μM Compound: Luteolin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay	[PMID: 29655613]
RAW264.7	IC₅₀	14.4 μM Compound: Luteolin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 29655613]
RAW264.7	IC₅₀	5.8 μM Compound: Luteolin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay	[PMID: 31419126]
RAW264.7	IC₅₀	8.1 μM Compound: 13	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]
RAW264.7	IC₅₀	>40 μM Compound: Lut.	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32208222]
RAW264.7	IC₅₀	9.2 μM Compound: Lut.	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 32208222]
RAW264.7	IC₅₀	1.2 μM Compound: 18; 39	Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in NO production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in NO production incubated for 24 hrs by Griess reagent based assay	[PMID: 37683361]
RBL-2H3	IC₅₀	82 μM Compound: Luteolin	Inhibition of rat RBL2H3 cell degranulation assessed as inhibition of beta-hexosamidase release after 10 mins by microplate reader assay Inhibition of rat RBL2H3 cell degranulation assessed as inhibition of beta-hexosamidase release after 10 mins by microplate reader assay	[PMID: 12398545]
RBL-2H3	IC₅₀	3.7 μM Compound: Luteolin	Inhibitory activity against IL-4 production in RBL-2H3 cells was determined Inhibitory activity against IL-4 production in RBL-2H3 cells was determined	[PMID: 12951092]
RBL-2H3	IC₅₀	5.8 μM Compound: Luteolin	Inhibitory activity against TNF-alpha production in RBL-2H3 cells was determined Inhibitory activity against TNF-alpha production in RBL-2H3 cells was determined	[PMID: 12951092]
RBL-2H3	IC₅₀	58.2 μM Compound: 6	Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge	[PMID: 14510616]
RS4-11	GI₅₀	7.25 μM Compound: 3	Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
SF-268	GI₅₀	9 μg/mL Compound: 4	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 12608861]
SW1573	IC₅₀	>10 μg/mL Compound: 9	Cytotoxicity against human SW1573 cells after 3 days by MTT assay Cytotoxicity against human SW1573 cells after 3 days by MTT assay	[PMID: 11421746]
THP-1	IC₅₀	70 μM Compound: Luteolin	Cytotoxicity against human THP1 cells after 24 hrs by MTS assay Cytotoxicity against human THP1 cells after 24 hrs by MTS assay	[PMID: 19879672]
THP-1	IC₅₀	70 μM/L Compound: Luteolin	Cytotoxicity against human THP1 cells after 24 hrs by MTS assay Cytotoxicity against human THP1 cells after 24 hrs by MTS assay	[PMID: 19879672]
U2OS	EC₅₀	3.2 μM Compound: Luteolin	Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay	[PMID: 24900447]
U-937	IC₅₀	20 μM Compound: 29, luteolin	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	28 μM Compound: 29, luteolin	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	36 μM Compound: 29, luteolin	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]
Vero	CC₅₀	22.9 μg/mL Compound: luteolin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 1338212]
Vero	CC₅₀	0.155 mM Compound: 13	Cytotoxicity against african green monkey Vero cells incubated for 3 days Cytotoxicity against african green monkey Vero cells incubated for 3 days	[PMID: 32539378]
Vero C1008	CC₅₀	0.155 μM Compound: 40	Cytotoxicity against African green monkey Vero E6 cells by MTT assay Cytotoxicity against African green monkey Vero E6 cells by MTT assay	[PMID: 33486200]
Vero C1008	EC₅₀	10.6 μM Compound: 40	Antiviral activity against wild type SARS-CoV BJ01 infected in Vero E6 cells assessed as reduction in viral replication incubated for 64 hrs by MTT dye based ELISA assay Antiviral activity against wild type SARS-CoV BJ01 infected in Vero E6 cells assessed as reduction in viral replication incubated for 64 hrs by MTT dye based ELISA assay	[PMID: 33486200]

In Vitro

Luteolin (0-160 μM; 24 hours; NCI-H460 cells) treatment inhibits the viability of NCI-H460 cells in a concentration-dependent manner^[1].
Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment causes an accumulation of cells in the S phase^[1].
Luteolin (320-580 μM; 48 hours; NCI-H460 cells) treatment induces apoptosis^[1].
Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment increases the protein expression levels of apoptotic regulatory proteins, including the Bax/Bcl-2 ratio, in a concentration-dependent manner, however, only 80 μM Luteolin inhibits the expression of Bad. Luteolin also decreases the expression of Sirt1 in the NCI-H460 cell line in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

NCI-H460 cells
Concentration:

0 µM, 20 µM, 40 µM, 80 µM and 160 µM
Incubation Time:

24 hours
Result:

Inhibited the viability of NCI-H460 cells in a concentration-dependent manner.

Cell Cycle Analysis^[1]

Cell Line:

NCI-H460 cells
Concentration:

20 µM, 40 µM, 80 µM
Incubation Time:

24 hours
Result:

Induced cell cycle arrest in the S phase.

Apoptosis Analysis^[1]

Cell Line:

NCI-H460 cells
Concentration:

320 µM, 440 µM, 580 µM
Incubation Time:

48 hours
Result:

Apoptotic fraction was markedly increased.

Western Blot Analysis^[1]

Cell Line:

NCI-H460 cells
Concentration:

20 µM, 40 µM, 80 µM
Incubation Time:

24 hours
Result:

Increased the protein expression levels of apoptotic regulatory proteins and decreased the expression of Sirt1 in the NCI-H460 cell line in a concentration-dependent manner.

In Vivo

Luteolin (10-100 mg/kg; oral gavage; daily; for 12 weeks; adult male Wistar rats) has an antioxidant effect and can also protect against non-alcoholic steatohepatitis through targeting the pro-inflammatory IL-1 and Il-18 pathways in rats with a high carbohydrate/high fat diet^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male Wistar rats (200-220 g)^[2]
Dosage:

10 mg/kg, 25 mg/kg, 50 mg/kg or 100 mg/kg
Administration:

Oral gavage; daily; for 12 weeks
Result:

Significantly reduced ALT and AST activity and reduced levels of bilirubin, hyaluronic acid and malondialdehyde. Shows an antioxidant activity such as a significant increase in reduced glutathione. IFN-γ, TNF-α, IL-1α and IL-18 levels decreased significantly.

Chemical Information

CAS No. 491-70-3
Appearance Solid
Molecular Weight 286.24
Formula C₁₅H₁₀O₆
Color Light yellow to yellow
SMILES

O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
Synonyms

Luteoline; Luteolol; Digitoflavone
Structure Classification
- Flavonoids
- Flavones
- Phenols
- Polyphenols
Initial Source
- Plants
- other families
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (90)

All IFBio/Physico-chemical AssayHistological Imaging/StainingCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

GALNT10 Affects O-Glycosylation of IGFBP7 to Promote Tumor Vascular Remodeling and Metastasis of Ovarian Cancer. [Abstract]

2026 Apr;13(19):e16106. PMID: 41637621
Adv Sci (Weinh)

Targeted Inhibition of CD74+ Macrophages by Luteolin via CEBPB/P65 Signaling Ameliorates Osteoarthritis Progression. [Abstract]

2025 Nov 21:e08472. PMID: 41268703
Theranostics

The m6A reader YTHDC2 promotes the pathophysiology of temporal lobe epilepsy by modulating SLC7A11-dependent glutamate dysregulation in astrocytes. [Abstract]

2024 Sep 3;14(14):5551-5570. PMID: 39310099

Luteolin purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Sep 3;14(14):5551-5570. [Abstract]

Luteolin (25 mg/kg, i.p., daily). Immunofluorescence analysis of astrocytes co-stained with NRF2 in the CA1 region of mice across different groups. Treatment with Luteolin, an NRF2 inhibitor, results in a reduction of NRF2 expression.
J Hazard Mater

Ammonia-induced exosomal miRNA disrupts autophagy and promotes lung injury: Therapeutic potential of natural compounds. [Abstract]

2026 Mar 15:506:141417. PMID: 41775203
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Food Chem

Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]

2023 Mar 30;405(Pt A):134807. PMID: 36370576
Cell Death Dis

Mechanisms and targeted prevention of abnormal ductular reaction caused by a low concentration of Benzo(a)pyrene. [Abstract]

2025 Oct 7;16(1):714. PMID: 41057340

Luteolin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Oct 7;16(1):714. [Abstract]

Luteolin (10 mg/kg; p.o.; daily for 4 weeks). Biochemical analysis of blood in NC, luteolin, B[a]P and B[a]P + luteolin groups.
Phytomedicine

Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]

2025 Dec 24:150:157740. PMID: 41477978
Phytomedicine

Study on the anti-liver cirrhosis of Fuzheng Huayu tablet : Targeting macrophage PPARα axis-fatty acid metabolic. [Abstract]

2025 Nov 22:150:157586. PMID: 41380414
Phytomedicine

Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer. [Abstract]

2025 Oct:146:157117. PMID: 40812220

Luteolin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Oct:146:157117. [Abstract]

Luteolin (0-100 μM; 48 h). Cell viability of MC38 and CT26 cells treated with varying concentrations of luteolin is assessed using the CCK-8 assay.
Phytomedicine

CBX5 loss drives Pl3Kδ inhibitor resistance in mantle cell lymphoma and propolis restores sensitivity by inducing CBX5-mediated ferroptosis. [Abstract]

2025 May 27:143:156911. PMID: 40466505
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Effect of luteolin on glioblastoma's immune microenvironment and tumor growth suppression. [Abstract]

2024 May 10:130:155611. PMID: 38776737

Luteolin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 May 10:130:155611. [Abstract]

Luteolin (60-120 μM; injected into the basal ganglia of the mice using a microsyringe; a total injection time of no less than 5 min). Hematoxylin and eosin staining of intracranial tumor plantation shows the tumor size in the coronal location of four groups.
Free Radic Biol Med

Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression. [Abstract]

2023 Nov 1:208:530-544. PMID: 37717793
Food Res Int

Glycyrrhiza uralensis Fisch: A novel source of analgesic activity through NaV1.8 sodium channel modulation. [Abstract]

2025 Dec;222(Pt 1):117620. PMID: 41267240
Biomed Pharmacother

Decrease in GPSM2 mediated by the natural product luteolin contributes to colon adenocarcinoma treatment and increases the sensitivity to fluorouracil. [Abstract]

2024 Jul:176:116847. PMID: 38823277
Antioxidants (Basel)

Bioactive Extracts and Constituents from Taraxacum mongolicum: Antioxidant, Anti-Inflammatory, Enzyme-Inhibitory, and Molecular Docking Studies. [Abstract]

2026 May 29;15(6):688. PMID: 42351994
Int J Nanomedicine

Targeted Sustained-Release Therapy for Vulnerable Atherosclerotic Plaques Using Luteolin-Loaded Nanoparticles. [Abstract]

2025 Dec 28:20:15883-15899. PMID: 41488864
Phytother Res

Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer. [Abstract]

2023 Nov;37(11):5315-5327. PMID: 37469042
Phytother Res

Luteolin combined with low-dose paclitaxel synergistically inhibits epithelial-mesenchymal transition and induces cell apoptosis on esophageal carcinoma in vitro and in vivo. [Abstract]

2021 Nov;35(11):6228-6240. PMID: 34494324
Ind Crops Prod

2026 Jan 22;241:122697.
Ind Crops Prod

2025 Dec 11;239:122458.
J Agric Food Chem

Interaction of Flavonoids with Zinc and Zinc-Containing Enzymes. [Abstract]

2022 May 25;70(20):6134-6144. PMID: 35544338
Cancer Cell Int

Network pharmacology and experimental verification-based strategy for exploring the mechanisms of luteolin in the treatment of osteosarcoma. [Abstract]

2023 Sep 25;23(1):213. PMID: 37749554
Chin Med

The combination of Schisandrin C and Luteolin synergistically attenuates hepatitis B virus infection via repressing HBV replication and promoting cGAS-STING pathway activation in macrophages. [Abstract]

2024 Mar 18;19(1):48. PMID: 38500179
Am J Chin Med

Identification of Flavonoid Compounds in Treating Alzheimer's Disease Based on Network Medicine Framework Strategy. [Abstract]

2025 Aug 30:1-32. PMID: 40884807
J Ethnopharmacol

Dandelion (Taraxacum mongolicum Hand. -Mazz.) extract inhibits triple-negative breast cancer by inducing ferroptosis via NCOA4-mediated ferritinophagy. [Abstract]

2026 May 23:363:121393. PMID: 41707813
Chem Biol Interact

Involvement of ductal reaction in Di-(2-ethylhexyl)-phthalate-caused hepatic fibrosis: Molecular mechanisms and potential intervention strategies. [Abstract]

2025 Sep 5:111738. PMID: 40915524
J Ethnopharmacol

Luteolin modulates macrophage phenotypic switching via the AMPK-PPARγ pathway to alleviate ulcerative colitis in mice. [Abstract]

2024 Nov 25:119157. PMID: 39603400
J Ethnopharmacol

Integrating UHPLC-Q-TOF-MS/MS, network pharmacology, bioinformatics and experimental validation to uncover the anti-cancer mechanisms of TiaoPi AnChang decoction in colorectal cancer. [Abstract]

2024 Jul 11:118576. PMID: 39002822
Food Funct

A Capsicum annuum L. seed extract exerts anti-neuroexcitotoxicity in HT22 hippocampal neurons. [Abstract]

2024 Feb 19;15(4):2144-2153. PMID: 38305768
J Ethnopharmacol

Research into the anti-pulmonary fibrosis mechanism of Renshen Pingfei formula based on network pharmacology, metabolomics, and verification of AMPK/PPAR-γ pathway of active ingredients. [Abstract]

2023 Dec 5:317:116773. PMID: 37308028
Int J Mol Sci

Luteolin Potentially Alleviates Methamphetamine Withdrawal-Induced Negative Emotions and Cognitive Deficits Through the AKT/FOXO1/HO-1 Signaling Pathway in the Prefrontal Cortex and Caudate Putamen. [Abstract]

2025 Jun 15;26(12):5739. PMID: 40565203
Biomolecules

Targeting Cellular Senescence to Enhance Human Endometrial Stromal Cell Decidualization and Inhibit Their Migration. [Abstract]

2025 Jun 16;15(6):873. PMID: 40563513
Front Pharmacol

Luteolin inhibits GPVI-mediated platelet activation, oxidative stress, and thrombosis. [Abstract]

2023 Oct 31:14:1255069. PMID: 38026984
Pharmaceuticals (Basel)

Luteolin Protects Pancreatic β Cells against Apoptosis through Regulation of Autophagy and ROS Clearance. [Abstract]

2023 Jul 7;16(7):975. PMID: 37513887
Front Pharmacol

Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway. [Abstract]

2021 Apr 15:12:663551. PMID: 33935785
Front Pharmacol

Exploring the Therapeutic Mechanism of Desmodium styracifolium on Oxalate Crystal-Induced Kidney Injuries Using Comprehensive Approaches Based on Proteomics and Network Pharmacology. [Abstract]

2018 Jun 13:9:620. PMID: 29950996

Luteolin purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 13:9:620. [Abstract]

Effects of Luteolin on the level of CTSD and p-CDK2 in HK-2 cells. The western blotting results of CTSD and p-CDK2 in the NaOx-stimulated HK-2 cells treated by Luteolin.
Eur J Pharmacol

NF-κB/TOM6/PINK1-mediated mitophagy attenuates vascular calcification: Luteolin as a therapeutic modulator. [Abstract]

2025 Dec 5:1008:178355. PMID: 41232657
Eur J Pharmacol

Luteolin targets peroxiredoxin 2 to augment T-cell-mediated cytotoxicity and suppress lung adenocarcinoma progression. [Abstract]

2025 Oct 5:1004:177984. PMID: 40712879
Bioorg Chem

Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies. [Abstract]

2024 Jun:147:107412. PMID: 38696845
Cancers (Basel)

Optimization of a Luteolin-Loaded TPGS/Poloxamer 407 Nanomicelle: The Effects of Copolymers, Hydration Temperature and Duration, and Freezing Temperature on Encapsulation Efficiency, Particle Size, and Solubility. [Abstract]

2023 Jul 24;15(14):3741. PMID: 37509402
Cancers (Basel)

Synergistic Combination of Luteolin and Asiatic Acid on Cervical Cancer In Vitro and In Vivo. [Abstract]

2023 Jan 16;15(2):548. PMID: 36672499
Poult Sci

Targeting TatD nuclease and the MAPK Pathway: Luteolin multifaceted approach against Mycoplasma gallisepticum infection. [Abstract]

2026 Jan 12;105(3):106426. PMID: 41548475
J Inflamm Res

Computational Systems Pharmacology, Molecular Docking and Experiments Reveal the Protective Mechanism of Li-Da-Qian Mixture in the Treatment of Glomerulonephritis. [Abstract]

2021 Dec 16;14:6939-6958. PMID: 34949932
Pestic Biochem Physiol

Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]

2025 Dec:215:106655. PMID: 41162045
J Chromatogr A

Quality by Design in optimizing the extraction of (poly)phenolic compounds from Vaccinium myrtillus berries. [Abstract]

2022 Aug 16:1677:463329. PMID: 35863094
Sci Rep

The mechanism of luteolin suppressing pancreatic cancer (PC) via cyclin B1 (CCNB1)-mediated signalling. [Abstract]

2025 Nov 26;15(1):42044. PMID: 41298459
Fish Shellfish Immunol

Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]

2025 Aug 6:166:110633. PMID: 40769268
Sci Rep

Mechanism of Brucea javanica against multiple myeloma via TNF-NF-κB signaling. [Abstract]

2025 Jul 7;15(1):24311. PMID: 40624153
Sci Rep

Study on the regulatory mechanism of luteolin inhibiting WDR72 on the proliferation and metastasis of non small cell lung cancer. [Abstract]

2025 Apr 11;15(1):12398. PMID: 40216870
Mol Divers

Investigating the molecular mechanism of epimedium herb in treating rheumatoid arthritis through network pharmacology, molecular docking, and experimental validation. [Abstract]

2025 Jan 16. PMID: 39821498
Eur J Med Res

Integrative analysis reveals luteolin's molecular targets and mechanisms in pancreatic cancer treatment. [Abstract]

2026 Mar 9. PMID: 41803987
Biochim Biophys Acta Mol Cell Biol Lipids

Lauric acid ameliorates excessive linoleic acid induced macrophage inflammatory response and oxidative stress in large yellow croaker (Larimichthys crocea). [Abstract]

2025 May 16:159635. PMID: 40383251
Comput Biol Chem

Integrated strategy of serum metabolomics, network pharmacology and experimental validation on revealing the bioactive metabolites and mechanism of Lycium ruthenicum Murr. against colorectal carcinoma. [Abstract]

2025 Oct 15;120(Pt 2):108721. PMID: 41105991
Naunyn Schmiedebergs Arch Pharmacol

Phytochemical characterization and multi-target mechanism of Gleditsia sinensis Fructus in lung adenocarcinoma treatment. [Abstract]

2025 Oct 29. PMID: 41160117
Naunyn Schmiedebergs Arch Pharmacol

Mechanism of Sophorae Flavescentis Radix against ovarian cancer via new pharmacology, molecular docking, and experimental verification. [Abstract]

2024 Sep;397(9):6837-6850. PMID: 38561549
Am J Physiol Endocrinol Metab

Luteolin alleviates polycystic ovary syndrome in rats by resolving insulin resistance and oxidative stress. [Abstract]

2021 Jun 1;320(6):E1085-E1092. PMID: 33900851
Ren Fail

Forecast and verification of the active compounds and latent targets of Guyuan decoction in treating frequently relapsing nephrotic syndrome based on network pharmacology. [Abstract]

2023 Dec;45(1):2184654. PMID: 36866869
Discov Oncol

Identification of potential molecular targets of luteolin in the treatment of hepatocellular carcinoma based on network pharmacology and transcriptome sequencing technology. [Abstract]

2025 Aug 8;16(1):1506. PMID: 40778996
Infect Drug Resist

Investigating the Therapeutic Mechanisms of Honeysuckle (China) in Sepsis Through Network Pharmacology and Experimental Validation. [Abstract]

2025 Jul 3:18:3257-3277. PMID: 40630747
Shock

A network pharmacology-based treatment analysis of luteolin for regulating pyroptosis in acute lung injury. [Abstract]

2023 Aug 1;60(2):306-314. PMID: 37379125
Int J Biochem Cell Biol

Luteolin prevents hyperoxaluria-induced renal injury by inhibiting crystal deposition and renal inflammation. [Abstract]

2026 May:194:106909. PMID: 41672398
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
BMC Pharmacol Toxicol

Effect of luteolin on oxidative stress and inflammation in the human osteoblast cell line hFOB1.19 in an inflammatory microenvironment. [Abstract]

2024 Jul 12;25(1):40. PMID: 38997762
Vet Microbiol

Luteolin restricts ASFV replication by regulating the NF-κB/STAT3/ATF6 signaling pathway. [Abstract]

2022 Oct:273:109527. PMID: 35961273
Toxicol In Vitro

Nonhomologous end joining and homologous recombination involved in luteolin-induced DNA damage in DT40 cells. [Abstract]

2020 Jun;65:104825. PMID: 32169435
Pharm Dev Technol

Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia. [Abstract]

2025 Nov;30(10):1543-1556. PMID: 41255224
Biomed Res Int

Network-Based Pharmacology and Bioinformatics Study on the Mechanism of Action of Gujiansan in the Treatment of Steroid-Induced Avascular Necrosis of the Femoral Head. [Abstract]

2022 Jul 23:2022:8080679. PMID: 35915795
Cancer Rep (Hoboken)

Unraveling the Anti-Tumor Effects and Molecular Mechanisms of Hairyvein Agrimonia Herb in Gastric Cancer Through Network Pharmacology and Experimental Validation. [Abstract]

2025 May;8(5):e70169. PMID: 40391580
Biol Pharm Bull

He-Wei-Decoction Ameliorates Chronic Atrophic Gastritis via Modulation of the TLR4/NF-κB Signaling Pathway. [Abstract]

2025;48(10):1514-1525. PMID: 41083380
Biol Pharm Bull

Regioselective Glucuronidation of Flavones at C5, C7, and C4' Positions in Human Liver and Intestinal Microsomes: Comparison among Apigenin, Acacetin, and Genkwanin. [Abstract]

2022;45(8):1116-1123. PMID: 35908893
Lett Drug Des Discov

2026 Jan 10.
Nat Prod Commun

2025 Dec 17.
Int Ophthalmol

Protective effects of luteolin on high glucose-induced ferroptosis in müller cells. [Abstract]

2025 Nov 19;45(1):494. PMID: 41258543
Medicine

Network pharmacology-based strategy for predicting therapy targets of Ecliptae Herba on breast cancer. [Abstract]

2023 Oct 13;102(41):e35384. PMID: 37832105
Int J Clin Exp Pathol

Myocyte enhancer factor 2D promotes hepatocellular carcinoma through AMOTL2/YAP signaling that inhibited by luteolin. [Abstract]

2022 May 15;15(5):206-214. PMID: 35698637
Res Sq

2026 Feb 24.
SSRN

2026 Jan 15.
bioRxiv

2025 Oct 3.
SSRN

2025 Jul 8.
Res Sq

2025 Jul 11.
Research Square Preprint

2023 Sep 18.
Phytomed Plus

2023 Sep 1, 100483.
Oxid Med Cell Longev

JFD, a Novel Natural Inhibitor of Keap1 Alkylation, Suppresses Intracellular Mycobacterium Tuberculosis Growth through Keap1/Nrf2/SOD2-Mediated ROS Accumulation. [Abstract]

2023 Feb 10:2023:6726654. PMID: 36819778
Contrast Media Mol Imaging

Luteolin Inhibited the Self-Renewal and Altered the Polarization of Primary Alveolar Macrophages. [Abstract]

2022 Aug 18:2022:3517020. PMID: 36051934
Oxid Med Cell Longev

HO-1 Contributes to Luteolin-Triggered Ferroptosis in Clear Cell Renal Cell Carcinoma via Increasing the Labile Iron Pool and Promoting Lipid Peroxidation. [Abstract]

2022 Apr 25;2022:3846217. PMID: 35656025
Evid Based Complement Alternat Med

Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification. [Abstract]

2021 Nov 27:2021:7765658. PMID: 34873410
Evid Based Complement Alternat Med

Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation. [Abstract]

2021 Aug 26:2021:7169211. PMID: 34484402

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (349.36 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4936 mL

17.4679 mL

34.9357 mL

5 mM

0.6987 mL

3.4936 mL

6.9871 mL

10 mM

0.3494 mL

1.7468 mL

3.4936 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 20 mg/mL (69.87 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 5 mg/mL (17.47 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ma L, et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis. Mol Med Rep. 2015 Sep;12(3):4196-4202. [Content Brief]

[2]. Abu-Elsaad N, et al. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin. Pharmacol Rep. 2019 Aug;71(4):688-694. [Content Brief]

[3]. Xiuwen Tang, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011 Jun 1;50(11):1599-609. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4936 mL	17.4679 mL	34.9357 mL	87.3393 mL
	5 mM	0.6987 mL	3.4936 mL	6.9871 mL	17.4679 mL
	10 mM	0.3494 mL	1.7468 mL	3.4936 mL	8.7339 mL
	15 mM	0.2329 mL	1.1645 mL	2.3290 mL	5.8226 mL
	20 mM	0.1747 mL	0.8734 mL	1.7468 mL	4.3670 mL
	25 mM	0.1397 mL	0.6987 mL	1.3974 mL	3.4936 mL
	30 mM	0.1165 mL	0.5823 mL	1.1645 mL	2.9113 mL
	40 mM	0.0873 mL	0.4367 mL	0.8734 mL	2.1835 mL
	50 mM	0.0699 mL	0.3494 mL	0.6987 mL	1.7468 mL
	60 mM	0.0582 mL	0.2911 mL	0.5823 mL	1.4557 mL
	80 mM	0.0437 mL	0.2183 mL	0.4367 mL	1.0917 mL
	100 mM	0.0349 mL	0.1747 mL	0.3494 mL	0.8734 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Luteolin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Flavonoids Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Luteolin

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (90)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Luteolin Related Classifications

Cat. No.: HY-N0162